Last reviewed · How we verify
NCT05593120
Evaluation of Health Economics for Noninvasive Coronary Fractional Flow Reserve Measurement Technology
trial testing CT-FFR in Coronary Artery Disease in 600 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Shenzhen Raysight Intelligent Medical Technology Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 29 June 2022 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- CT-FFR
- Routine care
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
Who can join
18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine whether, in a Chinese population of patients presenting to Wuhan Asia Heart Hospital, Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography (CT-FFR) as a default test is noninferior in terms of total costs when compared to routine clinical pathway recommended by the investigator and the institution's heart team.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05593120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CT-FFR
Trials testing the same drug.
- NCT05611190 — CT-FFR-guided Strategy for In-stent Restenosis · NA · unknown
- NCT06153927 — Diagnostic Performance of On-site Automatic Coronary Computed Tomography Angiography-derived Fractional Flow Reserve · completed
- NCT04939207 — Safety and Cost-efficiëncy of New Imaging Techniques in Patients Suspected of Coronary Artery Disease · NA · recruiting
- NCT04664439 — Follow-up With CT-FFR in CHD Patients After DCB · NA · unknown
- NCT03045601 — Diagnostic Accuracy of CT-FFR Compared to Invasive Coronar Angiography With Fractional Flow Reserve · NA · completed
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Shenzhen Raysight Intelligent Medical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT06039748 — Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study · completed
- NCT06032572 — Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) · NA · unknown
- NCT05320185 — Evaluation on the Effectiveness and Safety of RuiXin-CoronaryAI for Diagnosis of Coronary Artery Stenosis · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05593120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
- Last refreshed: 25 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05593120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing